AstraZeneca, Fasenra
Zacks.com on MSN17h
Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
AstraZeneca Pharma India to launch Palivizumab in India, a drug to prevent RSV in high-risk children. Stocks rise.
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca PLC AZN shares inched down 0.40% to £119.68 Tuesday, on what proved to be an all-around great trading session for ...
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the ...
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...
AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
AstraZeneca PLC AZN shares inched up 0.74% to £120.16 Monday, on what proved to be an all-around positive trading session for ...
London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...
Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback